This cavitation emissions-based feedback controller has been adopted in all our ongoing clinical trials beginning in late 2019, including studies on glioblastoma (GBM), Her2-positive brain metastases, Alzheimer’s disease, as well as this trial on PD. This evidence concerns the gene ERBB2 and Parkinson disease.